Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Open-Label, Randomized Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab Versus Daratumumab, Pomalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

NCT07742215 is registered in ClinicalTrials.gov with Biocad as lead sponsor.

NCT NCT07742215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07742215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Open-Label, Randomized Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab Versus Daratumumab, Pomalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Biocad
Phase
Phase 3
Overall status
Recruiting
Start date
June 15, 2026
Completion date
October 31, 2032
Enrollment
390 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

myeloma multiple